Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.

Sponsor
Fujian Cancer Hospital
Study ID
NCT05624099
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Digestive System Neoplasms
  • Esophageal Diseases
  • Esophageal Neoplasms

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • camrelizumab — DRUG
    200mg intravenous drip d1q3w
  • Paclitaxel drugs — DRUG
    150mg/m2 d1 q3w
  • Platinum drug — DRUG
    Cisplatin, carboplatin, nedaplatin and other platinum drugs
  • Radiation — RADIATION
    Dose: 5040cGy/28f

Study Details

This is a prospective single-arm exploratory clinical study. The efficacy and safety of camrelizumab combined with chemoradiotherapy and camrelizumab combined with chemotherapy were evaluated in patients with advanced esophageal cancer who had not previously received any systemic antitumor therapy for esophageal cancer.

Key Dates

Start date
Aug 1, 2023
Status verified
Oct 2023
Primary completion
Dec 1, 2025
Completion
Dec 31, 2027

Study Design

Enrollment
75 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: drug
    1. camrelizumab 200mg intravenous drip d1q3w 2. Paclitaxel: 150mg/m2 d1 q3w 3. Platinum: Cisplatin, carboplatin, nedaplatin and other platinum drugs 4. Radiotherapy dose: 5040cGy/28f radiotherapy efficacy evaluation after 2-3 cycles of chemotherapy PR/SD received local radiotherapy.

Primary Outcome Measure

Objective Response Rate(ORR) [ Time Frame: 3 years ]

Central Contacts

Related Studies